George Doherty - Concepedia

Author

George Doherty

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Alison Howarth, George A Doherty, George A. Doherty, George Doherty, Karina-Doris Vihta

Publications

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of Oxford Public Health England Oxford University Hospitals NHS Trust AbbVie (United States)

About

George Doherty is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	687
2	Natural Sciences	3	3	66
3	Public Health	2	2	229
4	Social Sciences	1	1	34
5	Allergy	1	1	44

George Doherty

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison Mark Ainsworth, Monique Andersson, Kathryn Auckland, The Lancet Infectious Diseases	2020	397
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers Sheila Lumley, Jia Wei, Denise O’Donnell, Clinical Infectious Diseases	2021	306
Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study David W. Eyre, Sheila Lumley, Denise O’Donnell, eLife	2020	282
Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey Koen B. Pouwels, Thomas House, Emma Pritchard, The Lancet Public Health Virus EpidemiologyEmerging Infectious DiseasesCovid-19 PandemicVirologyDisease Surveillance	2020	208
An Asymmetric Synthesis of the Tricyclic Core and a Formal Total Synthesis of Roseophilin via an Enyne Metathesis Barry M. Trost, George Doherty Journal of the American Chemical Society	2000	174
Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease Yutong Jiang, Steven W. Andrews, Kevin R. Condroski, Journal of Medicinal Chemistry Hepatitis C VirusImmunologyAntiviral DrugViral Structural ProteinHcv Ns3 Protease	2013	139
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> Inhibitor Le Wang, George Doherty, Andrew S. Judd, ACS Medicinal Chemistry Letters	2020	127
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status Sheila Lumley, Gillian Rodger, Bede Constantinides, Clinical Infectious Diseases	2021	82
N-Aryl 2,6-Dimethoxybiphenylalanine Analogues as VLA-4 Antagonists George Doherty, Theodore M. Kamenecka, Ermenegilda McCauley, Bioorganic & Medicinal Chemistry Letters N-aryl 2,6-Dimethoxybiphenylalanine AnaloguesMedicinePharmacological AgentPharmacotherapyPharmacology	2002	48
Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists Jeffrey J. Hale, George Doherty, Leslie M. Toth, Bioorganic & Medicinal Chemistry Letters Cardiovascular DiseaseFunctional SelectivityMedicineCardiovascular PharmacologyPharmacotherapy	2004	46

Page 1